Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Radford-Smith

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trialsDavid T Rubin, Iris Dotan, Aaron DuVall, et al.
Clinical and Translational Gastroenterology|January 29, 2021
Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac DiseaseJohn Croese, Gregory C Miller, Louise Marquart, et al.
BMJ Open|July 2, 2021
Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocolBonita Gu, Michael De Gregorio, Joseph Louis Pipicella, et al.
Gastroenterology|April 12, 2016
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on InfectionMette Julsgaard, Lisbet A Christensen, Peter R Gibson, et al.
World Journal of Gastroenterology|September 3, 2020
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and OxfordSamba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, et al.
Inflammatory Bowel Diseases|May 23, 2018
Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel DiseaseRebecca L Roberts, Mary C Wallace, Margien L Seinen, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's DiseaseEmily K Wright, Michael A Kamm, Peter De Cruz, et al.
Journal of Gastroenterology and Hepatology|December 16, 2016
Serologic antibodies in relation to outcome in postoperative Crohn's diseaseAmy L Hamilton, Michael A Kamm, Peter De Cruz, et al.
American Journal of Respiratory and Critical Care Medicine|November 26, 2019
Airway Mucus Hyperconcentration in Non-Cystic Fibrosis BronchiectasisKathryn A Ramsey, Alice C H Chen, Giorgia Radicioni, et al.
Inflammatory Bowel Diseases|December 3, 2025
Low Rates of Surgical Recurrence Following Ileocolic Resections for Crohn's Disease in the Biologic EraHugh L Giddings, Kheng-Seong Ng, Michael J Solomon, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trialsDavid T Rubin, Iris Dotan, Aaron DuVall, et al.
Clinical and Translational Gastroenterology|January 29, 2021
Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac DiseaseJohn Croese, Gregory C Miller, Louise Marquart, et al.
BMJ Open|July 2, 2021
Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocolBonita Gu, Michael De Gregorio, Joseph Louis Pipicella, et al.
Gastroenterology|April 12, 2016
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on InfectionMette Julsgaard, Lisbet A Christensen, Peter R Gibson, et al.
World Journal of Gastroenterology|September 3, 2020
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and OxfordSamba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, et al.
Inflammatory Bowel Diseases|May 23, 2018
Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel DiseaseRebecca L Roberts, Mary C Wallace, Margien L Seinen, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's DiseaseEmily K Wright, Michael A Kamm, Peter De Cruz, et al.
Journal of Gastroenterology and Hepatology|December 16, 2016
Serologic antibodies in relation to outcome in postoperative Crohn's diseaseAmy L Hamilton, Michael A Kamm, Peter De Cruz, et al.
American Journal of Respiratory and Critical Care Medicine|November 26, 2019
Airway Mucus Hyperconcentration in Non-Cystic Fibrosis BronchiectasisKathryn A Ramsey, Alice C H Chen, Giorgia Radicioni, et al.
Inflammatory Bowel Diseases|December 3, 2025
Low Rates of Surgical Recurrence Following Ileocolic Resections for Crohn's Disease in the Biologic EraHugh L Giddings, Kheng-Seong Ng, Michael J Solomon, et al.
Pageof 8